METHOD OF PRODUCING DRUG-CONTAINING WAX MATRIX PARTICLES, EXTRUDER TO BE USED IN THE METHOD AND SUSTAINED-RELEASE PREPARATION CONTAINING CILOSTAZOL

• US 20090047357A1
• Filed: 12/21/2006
• Published: 02/19/2009
• Est. Priority Date: 12/22/2005
• Status: Abandoned Application

• Current Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Original Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Inventors: Yamaguchi, Yasuo, Tomohira, Yuso
• Application Number:
  US12/158,529
• Publication Number:
  US 20090047357A1
• Time in Patent Office: Days
• US Class Current: 424/502
• CPC Class Codes: A61J 2200/20 Extrusion means, e.g. for producing pharmaceutical forms
• CPC Class Codes: A61J 3/06 into the form of pills, lozenges or dragees
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 9/148 with compounds of unknown constitution, e.g. material from plants or animals with oils, fats, waxes, shellac A61K9/145
• CPC Class Codes: B01J 2/20 by expressing the material, e.g. through sieves and fragmenting the extruded length

Abstract

The present invention aims to provide a method for producing, by a simple method, drug-containing wax matrix granules, particularly drug-containing wax matrix granules having an average particle diameter of 1 mm or lower, while avoiding liquid blockage due to the recrystallization of a molten drug during the period from a melting step to a spray step.

Drug-containing wax matrix granules having at least one wax and at least one drug are produced by the following steps (i) and (ii): (i) supplying the at least one drug and the at least one wax to an extruder in which the temperature of a barrel and the temperature of a die are adjusted to be higher than the melting point of the at least one wax; and (ii) while melting and kneading the at least one drug and the at least one wax in the extruder to give a molten kneaded drug and wax, spraying the molten kneaded drug and wax into an atmosphere having a temperature lower than the melting point of the wax from a spray nozzle directly mounted onto a die provided at a top end of the barrel of the extruder, thereby forming the mixture into granules.

Claims

1. A method for producing drug-containing wax matrix granules comprising at least one drug and at least one wax, the method comprising the steps of:

(i) supplying the at least one drug and the at least one wax to an extruder in which the temperature of a barrel and the temperature of a die are adjusted to be higher than the melting point of the at least one wax; and

(ii) while melting and kneading the at least one drug and the at least one wax in the extruder to give a molten kneaded mixture of the drug and wax, spraying the molten kneaded mixture of the drug and wax into an atmosphere having a temperature lower than the melting point of the wax from a spray nozzle directly mounted onto a die provided at a top end of the barrel of the extruder, thereby forming the mixture into granules.

2. The method according to claim 1, wherein the spray nozzle is a single-fluid nozzle, pressurization nozzle, two-fluid nozzle, or multi-fluid nozzle.

3. The method according to claim 1, wherein the extruder is a single-screw extruder, twin-screw extruder, or multi-screw extruder having at least three screws.

4. The method according to claim 1, wherein the drug-containing wax matrix granules are spherical.

5. The method according to claim 4, wherein the drug-containing wax matrix granules have an average particle diameter of 1 mm or less.

6. The method according to claim 1, wherein the at least one drug is at least one member selected from the group consisting of theophylline, cilostazol, ketoprofen, naproxen, diclofenac, itraconazole, piroxicam, phenyloin, verapamil, probucol and tolvaptan.

7. The method according to claim 1, wherein the at least one wax is at least one member selected from the group consisting of paraffin, micro crystallin wax, ceresin, Japan wax, cacao butter, carnauba wax, beeswax, cetanol, steryl alcohol, myristic acid, palmitic acid, stearic acid, glycerine fatty acid ester, polyglycerin fatty acid ester, glycerin organic-acid fatty acid ester, propylene glycol fatty acid ester, sorbitan fatty acid ester and hydrogenated oil.

8. The method according to claim 1, wherein the drug-containing wax matrix granules have 0.001 to 90% by weight of drug and 0.1 to 99.99% by weight of wax based on a total amount of the granules.

9. The method according to claim 1, wherein

(A) the at least one drug is cilostazol;

(B) the at least one wax is glycerol fatty acid ester and/or polyglycerol fatty acid ester; and

an average particle diameter of the drug-containing wax matrix granules ranges from 40 to 200 μ

m.

10. The method according to claim 9, further comprising the step (iii) of heating the granules prepared in the step (ii) at a temperature of 40 to 55°

C.

11. The production method according to claim 10, wherein, in the step (iii), inert particles are adhered to a surface of the granules obtained in the step (ii) before heating the granules at a temperature of 40 to 55°

C.

12. An extruder for producing drug-containing wax matrix granules, the extruder comprising:

a barrel having a temperature controller;

a supply port for supplying at least one drug and at least one wax to the barrel;

an outlet die provided in the barrel;

an extrusion screw for preparing a molten kneaded mixture of the at least one drug and the at least one wax and conveying the mixture to the outlet die, the extrusion screw being disposed within the barrel; and

a spray nozzle capable of spraying the molten kneaded mixture of the drug and wax, the spray nozzle being directly mounted on the outlet die.

13. The extruder for producing drug-containing wax matrix granules according to claim 12 further having a granule-forming chamber for solidifying the molten kneaded mixture of the drug and wax discharged from the spray nozzle to form granules.

14. A sustained-release preparation containing granules comprising:

(A) cilostazol crystals; and

(B) glycerol fatty acid ester and/or polyglycerol fatty acid ester; and

an average particle diameter of the granules ranges from 40 to 200 μ

m.

15. A sustained-release preparation according to claim 14, wherein an average particle diameter of the (A) cilostazol crystals is 10 μ

m or less.

16. A sustained-release preparation according to claim 14, wherein (A) the cilostazol crystals are present in a proportion of 5 to 60% by weight and (B) the glycerol fatty acid ester and/or polyglycerol fatty acid ester is/are present in a proportion of 30 to 95% by weight based on a total amount of the granules in the sustained-release preparation.

17. A sustained-release preparation according to claim 14, further comprising a water-soluble cellulose derivative.

18. A sustained-release preparation according to claim 17, wherein the water-soluble cellulose derivative is hydroxypropylmethylcellulose.

19. A sustained-release preparation according to claim 17, comprising 1 to 15% by weight of the water-soluble cellulose derivative based on a total amount thereof.

20. A sustained-release preparation according to claim 18, comprising 1 to 15% by weight of hydroxypropylmethylcellulose based on a total amount thereof.

21. A sustained-release preparation according to claim 14, wherein the granules comprising the ingredients (A) and (B) are granules prepared by solidifying a molten mixture of the ingredients (A) and (B).

22. A sustained-release preparation according to claim 14, wherein inert particles are adhered to a surface of the granules.

23. A sustained-release preparation containing cilostazol according to claim 22, wherein the inert particle is at least one member selected from the group consisting of talc, light anhydrous silicic acid, titanium oxides, and cellulose-based polymers.

24. A sustained-release preparation according to claim 14, wherein the ingredient (B) is at least one member selected from the group consisting of glycerol stearate, polyglycerol stearate, glycerol behenate, and polyglycerol behenate.

25. A sustained-release preparation according to claim 14, wherein the ingredient (B) is at least one member selected from the group consisting of glycerol behenate, diglycerol stearate, and triglyceryl half-ester of behenic acid.

26. A sustained-release preparation according to claim 14 prepared by steps (i) and (ii);

(i) supplying (A) cilostazol and (B) glycerol fatty acid ester and/or polyglycerol fatty acid ester to an extruder in which the temperature of a barrel and the temperature of a die are adjusted to be higher than the melting point of the ingredient (B); and

(ii) while melting and kneading the ingredients (A) and (B) in the extruder to give a molten kneaded mixture of the ingredients (A) and (B), spraying the molten kneaded mixture of the ingredients (A) and (B) into an atmosphere having a temperature lower than the melting point of the ingredient (B) from a spray nozzle directly mounted onto a die provided at a top end of the barrel of the extruder, thereby forming the mixture into granules.

27. A sustained-release preparation according to claim 26 prepared by supplying (C) a water-soluble cellulose derivative in addition to the ingredients (A) and (B) in the step (i).

28. A sustained-release preparation according to claim 26, prepared by further subjecting the granules obtained in the step (ii) to the step (iii) of heating the granules at 40 to 55°

C.

29. A sustained-release preparation according to claim 26 prepared by adhering, prior to the heating step in the step (iii), inert particles to a surface of the granules obtained in the step (ii).